Investors can have the blinders on to some extent when it comes to health care. Biotech and pharmaceutical stocks get the most buzz, but plenty of other companies that do business in the health care industry could be worthy of consideration. Buying�GE (NYSE: GE ) stock, for example, probably isn't on many investors' radar screens as a health-care play, but should it be? Let's take a look.
Bringing good things to life
While GE is a massive conglomerate spanning multiple industries, its GE Healthcare segment claims an important place within the company. Healthcare ranks as the fourth-largest segment overall in terms of revenue and the third-largest industrial segment.
Source: Company 10-K report.�
GE Healthcare posted 2012 revenue of $18.3 billion. Its products include a wide variety of medical equipment such as magnetic resonance imaging -- or MRI -- platforms, ultrasound systems, surgical imaging systems, patient monitoring technology,�and many others. The business segment goes beyond just medical equipment, though. GE Healthcare also sells electronic medical record systems, clinical consumable products, and technology used in drug discovery.
Hot Retail Stocks For 2015: Pharmacyclics Inc (PCYC)
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.
Advisors' Opinion:- [By John Udovich]
Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:
Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron�� where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs�Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech�IPO Setbacks. FierceBiotech has�summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia,�slashed its asking price on 6.9 million shares to $12 a share to raise $82 million�from a range of $16 to $19 a share while�Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer,�has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming�Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its�new, patient-friendly approach for delivering inhaled nitric oxide on the - [By Sean Williams]
What's perhaps more remarkable is the fact that Pharmacyclics (NASDAQ: PCYC ) has three of those 23 approved breakthrough therapy designations for its lead experimental drug, ibrutinib. Ibrutinib, which is also licensed to Johnson & Johnson (NYSE: JNJ ) subsidiary Janssen Pharmaceuticals, was designated as a breakthrough therapy for patients with chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. The big potential indication here is CLL, which is the most common adulthood leukemia and occurs in 113,000 people in the U.S. By comparison, MCL diagnoses number about 5,000 each year.
- [By Brian Orelli]
Johnson & Johnson (NYSE: JNJ ) announced on Monday that it had received a third Breakthrough Therapy Designation for the blood cancer drug ibrutinib that it's developing with Pharmacyclics� (NASDAQ: PCYC ) . The designation covers patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have a deletion of the short arm of chromosome 17.
10 Best Tech Stocks To Buy Right Now: Velti plc(VELT)
Velti plc provides mobile marketing and advertising solutions for mobile operators, ad agencies, brands, and media groups. The company?s Mobile Marketing Platform (MMP) helps businesses to plan, execute, monitor, and measure mobile marketing or advertising campaigns on various digital delivery channels, including Internet sites, SMS and MMS, mobile TV, mobile communities, mobile applications, location-based services, and mobile social networking. Its MMP also helps in the creation of mobile Websites, portals, blogs, content, iPhone applications, branded games, and mobile widgets; and in the mobile marketing through mobile clubs, mobile content, contests, couponing, alerts and tips, photo/text to screen, green screen, and image remix applications. In addition, MMP offers Mobile CRM solutions that help in the creation and management of mobile communities, mobile broadcasts, member management, segment management, member rewards, multichannel registration, and advanced profil ing. It has operations in Europe, North America, the Middle East, and Asia. The company was founded in 2000 and is based in London, the United Kingdom.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 name that's quickly moving within range of triggering a big breakout trade is Velti (VELT), which provides mobile marketing and advertising technology solutions that enable brands, advertising agencies, and mobile operators to implement interactive and measurable campaigns by communicating with and engaging consumers via their mobile devices. This stock has been destroyed by the bears so far in 2013, with shares off sharply by 91%.
If you take a look at the chart for Velti, you'll notice that this stock recently gapped down big from over $1 a share to 33 cents per share with monster downside volume. Following that gap down, shares of VELT have started to consolidate and move sideways between 33 cents per share on the downside and 44 cents per share on the upside. Shares of VELT are spiking sharply higher on Thursday above some near-term support at 35 cents per share. That move is pushing this stock within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in VELT if it manages to break out above some near-term overhead resistance at 44 cents per share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 2.02 million shares. If that breakout triggers soon, then VELT could easily explode higher and potentially re-test its gap down day high from August at 66 cents per share.
Traders can look to buy VELT off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at 35 cents to 33 cents per share. One can also buy VELT off strength once it clears 44 cents per share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
10 Best Tech Stocks To Buy Right Now: Gilat Satellite Networks Ltd.(GILT)
Gilat Satellite Networks Ltd. provides Internet Protocol (IP) based digital satellite communication and networking products and services worldwide. The company engages in the design, production, and marketing of very small aperture terminals (VSATs) and related VSAT network equipment, such as power amplifiers and low-profile antennas. Its VSAT products include SkyEdge and SkyEdge II products that deliver broadband connectivity, such as Internet, voice, data, and video services. The company also provides Spacenet managed network communications services through satellite networks and hybrid satellite terrestrial networks; and Wavestream solid state power amplifiers to system integrators that serve various defense and homeland security agencies. It also offers SkyAbis solution that provides cellular backhaul for rural communications; Connexstar networks that are standardized commercial grade satellite services; and StarBand satellite Internet services, which are geared for sm all office and residential users. In addition, the company provides various solutions, including project management, network design, deployment logistics, implementation and integration, operational services, and maintenance and support. It sells its products primarily to communication service providers and operators that use VSATs to serve enterprise, government, and residential users, as well as directly to end-users. Gilat Satellite Networks Ltd. was founded in 1987 and is headquartered in Petah Tikva, Israel.
Advisors' Opinion:- [By James Miller Phd]
The company has a current ratio of 13.05% which is higher than the one registered by Charter Communications Inc. (CHTR), Digital Globe Inc. (DGI), EchoStar Corp (SATS), Gilat Satellite Networks Ltd. (GILT) and Intelsat SA (I).
10 Best Tech Stocks To Buy Right Now: Actuate Corp (BIRT)
Actuate Corporation (Actuate), incorporated in November 1993, provides software and services to develop and deploy custom Business Intelligence and information applications. Actuate offers ActuateOne to develop and deploy Business Intelligence and Reporting Tools (BIRT)-based custom Business Intelligence and information applications focusing on browsers and mobile devices that deliver content hosted in cloud, software-as-a-service (SaaS) and on premises deployments. Its products and services are used by its customers to develop and deploy applications across a range of business functions, including financial management, sales management, account management, and customer self-service. Xenos solutions, based on Xenos Enterprise Server, loads, transforms and presents high volumes of data and documents across multiple channels. Actuate�� BIRT Spreadsheet products are Excel-based. In February 2014, Actuate Corporation announced the acquisition of legodo ag.
ActuateOne-Business Intelligence, Analytics and Reporting
Actuate offers a range of BIRT-based Business Intelligence (BI), analytics and reporting features within the integrated ActuateOne platform, providing 64-bit, in-memory analytics, user configurable dashboards, ad-hoc query, interactive mobile and Web content, brochure-quality reporting, and spreadsheet analysis. ActuateOne provides a platform upon which Global 9000 and packaged application software vendors develop and deploy BI and information applications. Such applications retrieve business information from databases, as well as print streams and deliver it as dashboards, interactive Web pages, spreadsheets, mobile content and analytic cubes to customers, partners and employees worldwide.
Xenos Enterprise Server Framework
Xenos Enterprise Server (ES) is an application that captures, identifies, routes, stores and retrieves structured and unstructured documents and data. Xenos ES supports the processing, extraction, transformation, repurposi! ng and personalization of structured and unstructured data in both legacy and SOA environments. Xenos ES distributes documents across multiple channels, such as Web, mobile and tablet devices in addition to providing interactivity and document analytics through its integration with ActuateOne.
Performance Analytics
Actuate BIRT Performance Analytics provides interactive dashboards, analytics, and scorecards. With Web interface, users across the enterprise can monitor operations, identify and analyze performance issues and enact initiatives.
BIRT Spreadsheet
Actuate�� BIRT Spreadsheet products deliver Excel-like reporting, formatting and calculation functionality within Java applications. Actuate BIRT Spreadsheet products can also leverage all the Actuate deployment options-embedded in applications or deployed cloud or on-premise enterprise environments.
The Company competes with Information Builders, Qlik Tech, Pentaho, Jaspersoft, MicroStrategy, IBM, Microsoft, Oracle and SAP.
Advisors' Opinion:- [By Roberto Pedone]
Actuate (BIRT) provides software solutions and services to corporate and government customers worldwide. This stock closed up 1.7% to $4.54 in Tuesday's trading session.
Tuesday's Range: $4.43-$4.57
52-Week Range: $3.41-$8.23
Tuesday's Volume: 213,000
Three-Month Average Volume: 319,262From a technical perspective, BIRT trended modestly higher here back above its 50-day moving average of $4.51 with lighter-than-average volume. This move to the upside on Tuesday is starting to push shares of BIRT within range of triggering a major breakout trade. That trade will hit trigger if BIRT manages to take out some key overhead resistance levels at $4.60 to $4.75 and then above more resistance at $4.85 with high volume.
Traders should now look for long-biased trades in BIRT as long as it's trending above some key near-term support levels at $4.30 to $4.25 and then once it sustains a move or close above those breakout levels with volume that hits near or above 319,262 shares. If that breakout starts soon, then BIRT will set up to re-fill some of its previous gap-down-day zone from May that started near $6.
10 Best Tech Stocks To Buy Right Now: Diebold Inc (DBD)
Diebold, Incorporated, incorporated in August 1876, is engaged in providing integrated self-service delivery and security systems and services to the financial, commercial, government and retail markets. Sales of systems and equipment are made directly to customers by the Company�� sales personnel, manufacturers��representatives and distributors globally. The sales and support organizations work closely with customers and their consultants to analyze and fulfill the customers��needs. The Company has two lines of business: Self-Service Solutions and Security Solutions. The Company�� segments are consisted of two sales channels: Diebold North America (DNA) and Diebold International (DI). In September 2012, it acquired GAS Tecnologia (GAS).
The DNA segment sells and services financial and retail systems in the United States and Canada. The DI segment sells and services financial and retail systems over the remainder of the globe through wholly owned subsidiaries, joint ventures and independent distributors in countries throughout Europe, the Middle East, Africa, Latin America and in the Asia Pacific region, excluding Japan and Korea.
Self-Service Solutions
The Company offers an integrated line of self-service technologies and services, including comprehensive automated teller machine (ATM) outsourcing, ATM security, deposit and payment terminals and software. The Company is a global supplier of ATMs and related services. The Company offers a range of self-service solutions. Self-service products include a range of ATMs and teller automation, including deposit automation technology, such as check-cashing machines, bulk cash recyclers and bulk check deposit. The Company offers software solutions consisting of multiple applications, which process events and transactions. These solutions are delivered on the appropriate platform. From analysis and consulting to monitoring and repair, the Company provides value and support to its customers every step of the way. ! Services include installation and ongoing maintenance of its products, OpteView remote services, branch transformation and distribution channel consulting. Outsourced and managed services include remote monitoring, troubleshooting for self-service customers, transaction processing, currency management, maintenance services and full support through person to person or online communication.
Security Solutions
The Company provides its customers with the technological advances to protect their assets. The Company provides physical and electronic security systems, as well as facility transaction products, which integrate security, software and assisted-service transactions, providing total security systems solutions to financial, retail, commercial and government markets. The Company provides security solutions and facility products, including in-store bank branches, pneumatic tube systems for drive-up lanes, vaults, safes, depositories, bullet-resistive items and undercounter equipment. The Company provides a range of electronic security products, including digital surveillance, access control systems, biometric technologies, alarms and remote monitoring and diagnostics. The Company provides security monitoring solutions, including fire, managed access control, energy management, remote video management and storage, as well as logical security.
Integrated Solutions
The Company provides end-to-end outsourcing solutions with a single point of contact for customer�� self-service channel. Its solution includes hardware, software, services or a combination of all three components. The Company provides value to its customers by offering a range of integrated services and support. The Company�� service organization provides analysis and planning of new systems, systems integration, architectural engineering, consulting and project management, which encompass all facets of a financial self-service implementation. The Company also provides design, products, ser! vice, ins! tallation, project management and monitoring of electronic security products to financial, government, retail and commercial customers.
Election Systems
The Company is a provider of voting equipment and related products and services in Brazil. The Company provides elections equipment, networking, tabulation and diagnostic software development, training, support and maintenance.
The Company competes with NCR Corporation, Wincor-Nixdorf, Grg Equipment Co., Nautilus Hyosung, Itautec and Perto.
Advisors' Opinion:- [By Rich Smith]
North Canton, Ohio-based Diebold (NYSE: DBD ) has a new CEO.
On Thursday, the manufacturer of "ATM" machines announced it has named Andy W. Mattes as the company's new president and chief executive officer. Mattes was chosen after a four-month search, and plucked from a position as senior vice president for global strategic partnerships at flash memory maker Violin Memory. He is keeping an advisory role at Violin, even as he takes over the top job at Diebold.
- [By Mark Morelli]
How will the potential disruption impact business and affect investors? Should the executives at ATM manufacturers such as Diebold (NYSE: DBD ) �be worried? Credit�and debit card processors like MasterCard (NYSE: MA ) and Visa (NYSE: V ) �are already benefiting from the trend to a cashless society. Could things get even better?
10 Best Tech Stocks To Buy Right Now: Acorn Energy Inc.(ACFN)
Acorn Energy, Inc., through its subsidiaries, provides technology driven solutions for energy infrastructure asset management worldwide. It offers sonar and acoustic related solutions for energy, defense, and commercial markets with a focus on underwater site security for strategic energy installations and other acoustic systems, as well as develops and produces real-time embedded hardware and software. The company also develops and markets remote monitoring systems to electric utilities and industrial facilities, which are used in a range of utility applications, including outage management, power quality monitoring, system planning, trouble shooting and proactive maintenance, and condition monitoring; and provides the intelligence to transmission and distribution network operators. In addition, it develops and produces fiber optic sensing systems for the energy, commercial security, and defense markets. The company?s patented ultra-high sensitivity fiber optic sensors a re designed to replace electronic sensors with fiber optic sensors. Further, it engages in the design, manufacture, marketing, and sale of wireless remote systems that monitor standby power generation, backup power generators, remote powered equipment, cellular towers, emergency towered communications, and remote tower sites; cathodic protection products to monitor pipeline integrity; and other wireless remote systems. Acorn Energy, Inc. was founded in 1986 and is based in Montchanin, Delaware.
Advisors' Opinion:- [By Roberto Pedone]
A technology stock that's starting to move within range of triggering a big breakout trade is Acorn Energy (ACFN), which provides digital solutions for energy infrastructure asset management. This stock has been hit hard by the sellers in 2013, with shares off sharply by 48%.
If you take a look at the chart for Acorn Energy, you'll notice that this stock has started to spike higher here back above its 50-day moving average of $3.66 a share. This stock has also found significant buying interest over the last two months, each time it has pulled back to around $3.50 to $3.20 a share. Shares of ACFN are now quickly moving within range of triggering a big breakout trade above some key near-term overhead resistance levels.
Traders should now look for long-biased trades in ACFN if it manages to break out above some key near-term overhead resistance levels at $4.24 to $4.64 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 344,835 shares. If that breakout triggers soon, then ACFN will set up to re-test or possibly take out its next major overhead resistance levels at $5.50 to $6 a share. Any high-volume move above $6 will then put its next major overhead resistance levels at its 200-day moving average of $6.35 to $6.68 a share into range for shares of ACFN.
Traders can look to buy ACFN off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $3.66 a share, or right around some major support at $3.21 a share. One could also buy ACFN off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Bryan Murphy]
Neither Acorn Energy Inc. (NASDAQ:ACFN) nor Cardica, Inc. (NASDAQ:CRDC) may look all that compelling with just a passing glance. The longer one examines CRDC and ACFN, however - and really gets a grasp of their underlying stories - the more compelling each one becomes. In fact, newcomers may want to go ahead and put both budding stocks on their watchlists, if not in their portfolios.
10 Best Tech Stocks To Buy Right Now: Universal Display Corporation(PANL)
Universal Display Corporation engages in the research, development, and commercialization of organic light emitting diode (OLED) technologies and materials for use in flat panel display, solid-state lighting, and other product applications. It owns exclusively license or has the sole right to sublicense approximately 1,400 patents issued and pending worldwide. The company licenses and supplies its proprietary UniversalPHOLED phosphorescent OLED technologies and materials to display manufacturers and others. It is also involved in the research, development, and commercialization of other OLED device and manufacturing technologies, including TOLED, which are transparent OLEDs for the fabrication of OLEDs that have transparent cathodes; FOLED that are flexible OLEDs for the fabrication of OLEDs on flexible substrates; OVPD, an organic vapor phase deposition process to deposit the layers of organic material in an OLED; UniversalP2OLED, which are printable phosphorescent OLEDs; OVJP that is an organic vapor jet printing technology; and encapsulation technology for the packaging of flexible OLEDs and other thin-film devices, as well as for use as a barrier film for plastic substrates. In addition, the company provides technology development and support services to third parties for the commercialization of their OLED products. It has strategic relationships with Samsung Mobile Display Co., Ltd.; LG Display Co., Ltd.; AU Optronics Corporation; Sony Corporation; Pioneer Corporation; Panasonic Idemitsu OLED Lighting Co., Ltd.; Tohoku Pioneer Corporation; Moser Baer Technologies, Inc.; Konica Minolta Holdings, Inc.; Denko K.K.; LG Chem, Ltd.; Panasonic Electric Works Co., Ltd.; NEC Lighting, Ltd.; Seiko Epson Corporation; and DuPont Displays, Inc. The company was founded in 1985 and is based in Ewing, New Jersey.
Advisors' Opinion:- [By Seth Jayson]
Universal Display (Nasdaq: PANL ) is expected to report Q1 earnings on May 9. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Universal Display's revenues will expand 13.7% and EPS will remain in the red.
No comments:
Post a Comment